hunterdon pharmaceuticals inc said formed joint venture with and develop c31g substance may useful treatment prevention plaque substance tested pre clinical trials university pennsylvania also has uses anti fungal anti bacterial agent company said said chesapeake biological private company owns pct venture michaels pct while holds remaining interest and patent for c31g reuter 